5063882F-6377-4976-BB48-7275D46C44E6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.64520367936925
- age_years
- 59
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.632
- INTERFERON_GAMMA_RESPONSE+0.613
- IL6_JAK_STAT3_SIGNALING+0.569
- ALLOGRAFT_REJECTION+0.564
- INFLAMMATORY_RESPONSE+0.553
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.542
- E2F_TARGETS+0.541
- TNFA_SIGNALING_VIA_NFKB+0.526
- ANGIOGENESIS+0.495
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.462
Top 10 suppressed
- KRAS_SIGNALING_DN-0.251
- SPERMATOGENESIS-0.084
- MITOTIC_SPINDLE-0.052
- PROTEIN_SECRETION-0.036
- HEDGEHOG_SIGNALING-0.030
- MYOGENESIS-0.022
- WNT_BETA_CATENIN_SIGNALING+0.004
- HEME_METABOLISM+0.064
- UV_RESPONSE_DN+0.087
- APICAL_JUNCTION+0.104
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.978 |
| 2 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.965 |
| 3 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.962 |
| 4 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.956 |
| 5 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.955 |
| 6 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.955 |
| 7 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.953 |
| 8 | 8976C50F-B340-488D-B9C1-12CCAC780397 | — | — | 0.952 |
| 9 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.951 |
| 10 | 3027792F-79B6-4729-9452-C4A72A7C4686 | — | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.632 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.613 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.569 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.564 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.553 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.542 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.541 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.526 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.495 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.462 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.461 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.456 | Idelalisib | — uncovered |
| APOPTOSIS | 0.454 | Idelalisib | — uncovered |
| COMPLEMENT | 0.447 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.426 | Inavolisib | — uncovered |
| HYPOXIA | 0.401 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.396 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.384 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.380 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.376 | Inavolisib | — uncovered |